HDAC9 and angioimmunoblastic T-cell lymphoma: Recently, immunomodulators, epigenetic drugs, and targeted therapies have shown great potential in AITL (20, 21), especially HDAC inhibitors such as chidamide and romidepsin, which have been approved in patients with relapsed or refractory PTCLs (12, 22).